LifeStance Health Group financials
$11.89+0.42%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $435.4M | $403.5M | $382.2M | $363.8M | $345.3M | $333.0M | $325.5M | $312.7M | $312.3M | $300.4M | $280.6M | $262.9M |
| Gross profit | $153.0M | $135.9M | $126.3M | $116.6M | $108.4M | $109.8M | $109.4M | $100.4M | $97.8M | $94.7M | -$473.0M | $262.9M |
| Gross margin | 35.2% | 33.7% | 33.0% | 32.0% | 31.4% | 33.0% | 33.6% | 32.1% | 31.3% | 31.5% | −168.6% | 100.0% |
| Operating income | $30.2M | $21.6M | $18.0M | $7.4M | -$3.0M | $1.6M | -$131.0K | $47.0K | -$16.7M | -$16.8M | -$32.4M | -$74.4M |
| Net income | $23.6M | $14.2M | $11.7M | $1.1M | -$3.8M | $709.0K | -$7.1M | -$6.0M | -$23.3M | -$21.1M | -$45.0M | -$61.6M |
| Net margin | 5.4% | 3.5% | 3.1% | 0.3% | −1.1% | 0.2% | −2.2% | −1.9% | −7.5% | −7.0% | −16.0% | −23.4% |
| Diluted EPS | $0.06 | $0.04 | $0.03 | $0.00 | $-0.01 | $0.00 | $-0.02 | $-0.02 | $-0.06 | $-0.06 | $-0.12 | $-0.17 |
| EBITDA | $44.5M | $34.9M | $31.4M | $21.0M | $11.1M | $15.4M | $14.5M | $15.2M | $1.9M | $5.8M | -$32.4M | -$54.7M |
| Operating cash flow | $99.9M | $33.1M | $57.6M | $27.3M | $64.4M | -$3.1M | $62.3M | $22.7M | $44.1M | -$21.8M | $16.8M | -$25.4M |
| Free cash flow | $87.9M | $22.3M | $46.6M | $17.0M | $56.6M | -$10.3M | $56.0M | $17.7M | $39.0M | -$26.9M | $5.4M | -$35.2M |
| Diluted shares | 387.3M | 395.1M | 398.3M | 388.9M | 386.7M | 390.7M | 380.5M | 380.4M | 379.4M | 376.3M | 373.3M | 372.5M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $225.9M | $194.8M | $248.6M | $203.9M | $188.9M | $134.3M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $259.0M | $262.5M | $265.9M | $269.4M | $272.9M | $276.3M |
| Total assets | $2.18B | $2.15B | $2.20B | $2.15B | $2.15B | $2.10B |
| Total liabilities | $704.3M | $668.5M | $682.9M | $656.2M | $672.9M | $647.6M |
| Shareholders' equity | $1.48B | $1.48B | $1.52B | $1.49B | $1.47B | $1.46B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology